Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Systematic review to compare the outcomes associated with the modalities of expanded hemodialysis (HDx) versus high-flux hemodialysis and/or hemodiafiltration (HDF) in patients with end-stage kidney disease (ESKD)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro
Visit resource site
PD
Temporal evolution in the selection of apd cycler-embedded remote patient management flag alerts by health care practitioners (HCPs): lessons to accelerate the RPM learning curve? - Firanek C et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Budgetary Impact of Introducing HDx therapy enabled by Theranova Dialyzer compared to High Flux Hemodialysis in private sector in the Kingdom of Saudia Arabia
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Cardiovascular Burden in End-Stage Renal Disease
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Comparison of Vancomycin Removal Between Medium Cut-Off(Theranova®) and Other Dialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The Efficacy of Post-Dilution Online Hemodiafiltration and Medium Cut-Off Dialyser on the Removal of Protein-Bound Uremic Toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease
Visit resource site
PD
The impact of a remote monitoring system of healthcare resource consumption in patients on automated peritoneal dialysis (APD): A simulation study - Uchiyama et al.
Visit resource site
PD
The Impact of Automated Peritoneal Dialysis (APD) with Remote Patient Management (RPM): Changing the Nursing Paradigm to Proactive Clinical Management - Firanek CA, et al.
Download PDF
HDx therapy enabled by the Theranova Dialyzer
The Medium Cut-Off Membrane Does Not Lower Protein-Bound Uremic Toxins
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
The optimized anticoagulation strategy in prolonged hemodialysis.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.